Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III)

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Angel Pharmaceuticals
Angel PharmaceuticalsChina - Zhejiang
1 program
1
Nonavalent HPV vaccinePhase 4Vaccine1 trial
Active Trials
NCT05334706RecruitingEst. Dec 2026

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Angel PharmaceuticalsNonavalent HPV vaccine

Clinical Trials (1)

NCT05334706Angel PharmaceuticalsNonavalent HPV vaccine

A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)

Start: Sep 2022Est. completion: Dec 2026
Phase 4Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials
1 companies competing in this space